= Additional active ingredients
Valsartan 160 mg.
PRESENTATION AND DOSSAGE
TABS: 28 X 160
Treatment of heart failure (NYHA class II-IV) in patients who are intolerant of angiotensin converting enzyme inhibitors. In a controlled clinical trial Valsartan significantly reduced hospitalisations for heart failure. There is no evidence that Valsartan provides added benefits when it is used with an adequate dose of an ACE inhibitor. Also indicated to improve survival following myocardial infarction in clinically stable patients with signs, symptoms or radiological evidence of left ventricular failure and/or with left ventricular systolic dysfunction.
Hypersensitivity to components, pregnancy, lactation, severe hepatic impairment, biliary obstruction, cirrhosis.
Sodium and/or volume-depleted patients. Sodium and/or volume depletion should be corrected before starting treatment. In mild to moderately hepatically impaired patients, a lower dose is recommended, and 80 mg should not be exceeded. In patients with heart failure, concomitant use of Diovan, an ACE inhibitor and a beta blocker is not recommended. In patients with bilateral or unilateral renal artery stenosis, monitoring is recommended as a safety measure. Caution when driving or operating machinery.
In general, mild and transient in nature. Fatigue, syncope, diarrhea, liver function abnormalities, thrombocytopenia, arthralgia, myalgia, headache, dizziness, mild and transient taste disturbance, renal dysfunction and isolated cases of renal impairment, cough, epistaxis.
Glibenclamide, potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium.
MANUFACTURER & DISTRIBUTER:
Manufacturer: Dexcel Pharma Technologies
License Holder: Dexcel Ltd.